At Rapid Defense, we believe the human body can heal itself, mainly when the immune system works properly. That’s why we’re dedicated to developing therapies and wellness supplements that work with the body, not against it.
We focus on folate and pterin-based immunotherapies, an advanced approach that helps retrain and restore immune function in patients facing severe health challenges.
Whether it’s cancer, sepsis, pneumonia, trauma, or ARDS, our treatments are designed to support the body’s natural defenses and improve its response to illness.
We combine medical science with deep care for patient outcomes. With ImmunoFolate and ImmunoPterin, we aim to provide solutions that fight disease and strengthen the body’s healing abilities safely, effectively, and compassionately.
We are dedicated to transforming the treatment of immune-related diseases through targeted immunotherapies.
ImmunoFolate and ImmunoPterin therapies are rooted in immunological science and designed to support immune reprogramming in oncology and critical care settings.
We specialize in addressing immune dysfunction at its root, aiming to improve survival and recovery in life-threatening conditions like NSCLC, sepsis, and ARDS.
ImmunoFolate
A next-generation, folate-based immunotherapy that reprograms immune cell behavior in patients with non-small cell lung cancer (NSCLC).
ImmunoFolate enhances immune system function, reduces immunosuppression within the tumor microenvironment, and improves treatment outcomes when used alongside conventional therapies.
Key Hypothesized Benefits:
● Targets folate receptor pathways
● Enhances antigen presentation and T-cell activation
● Reduces tumor-induced immune evasion
ImmunoPterin
ImmunoPterin addresses systemic inflammation and immune dysregulation in acute care scenarios such as ARDS, sepsis, pneumonia, and trauma.
This immunotherapy works by modulating cytokine release, supporting immune balance, and reducing the risk of organ damage.
Key Hypothesized Benefits:
● Supports immune homeostasis
● Helps regulate cytokine storms
● Complements critical care protocols
Rapid Defense's immunotherapies are designed for conditions where immune dysfunction drives disease progression. They include;
We are committed to supporting everyone involved in the treatment journey — from the healthcare professionals delivering care to the patients and caregivers living it every day. Our goal is to provide clear, reliable, and practical information tailored to each group’s needs.
We equip medical experts with the resources they need to make informed treatment decisions and provide the best possible patient care. Our offerings include:
We believe knowledge empowers patients and their families to face treatment with confidence. Our patient and caregiver resources are designed to be clear, compassionate, and easy to understand:
By serving both medical professionals and the people they care for, we aim to create a healthcare experience built on trust, clarity, and partnership.
We are preparing a phase 1/2 clinical trial of Immunofolate for patients with ARDS, non-small cell lung cancer, and metastatic colorectal cancer.
With our trial protocol complete, we are now pursuing FDA IND clearance while raising $10 million in seed funding to advance ImmunoFolate™ into clinical development.
Rapid Defense Inc. was founded by Phillip Moheno, Ph.D., a leader in immunotherapy with a passion for developing groundbreaking treatments that harness the body’s natural defenses. With decades of research expertise, Dr. Moheno envisioned a company that will deliver therapies that are both innovative and accessible.